Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07008664 · ClinicalTrials.gov registry record
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
A clinical trial of Lung Cancer and Lung Cancer Screening, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- 750
- Enrollment target
- 1
- Study location
NCT07008664: Recruiting study of Lung Cancer and Lung Cancer Screening, sponsored by University of Maryland, Baltimore.
NCT07008664 is a study of Lung Cancer and Lung Cancer Screening that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 750 participants, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07008664, a study of Lung Cancer and Lung Cancer Screening, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Primary Outcome
Genome-wide methylation profile of whole blood from lung cancer patients, pre-cancer patients, patients undergoing therapy, and control subjects.
Conditions Studied
Interventions
- OTHER Epigenetic Signature Assay
Study Locations (1)
Maryland
- University of Maryland Baltimore Washington Medical Center - Glen Burnie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2032-04 |
What NCT07008664 shows while recruiting
NCT07008664 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (20% lower).
The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Epigenetic Signature Assay is the first listed.
NCT07008664 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07008664 about?
NCT07008664 is a clinical study titled "Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer". The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood sample...
What is the current status of trial NCT07008664?
This trial is currently recruiting. The enrollment target is 750 participants. The study started on 2025-03-31. Estimated completion is 2032-04.
What conditions does trial NCT07008664 study?
This clinical trial studies the following conditions: Lung Cancer, Lung Cancer Screening, Healthy Volunteers (HV), Unhealthy Volunteers.
What interventions are being tested in trial NCT07008664?
The interventions under investigation include: Epigenetic Signature Assay (OTHER).
Who is sponsoring clinical trial NCT07008664?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07008664 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07008664's enrollment target sits among peer trials
750 58th of 409 higher than 351 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI